Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dengshan: Adjuvant Endostar + NP vs NP in Resected NSCLC
NCT01124253Phase 3Completed
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jul 2007
- Primary completion
- Oct 2009
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of endostar in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Overall Survival at 5 years. Started Jul 2007; status: completed.
02
Drugs
endostar
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01124253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01124253.